Robert Arch, PhD, and Tomas Hode, PhD, will connect with the global interventional oncology community September 5–9. Immunophotonics will attend the CIRSE 2026 Annual Congress, taking place September 5–9 in Copenhagen, Denmark. The congress is a major annual event for the interventional radiology community and has played an important role in helping Immunophotonics build relationships,...
Immunophotonics, Inc. announced two important milestones supporting the company’s continued advancement of Interventional Immuno-Oncology®: the closing of more than $10 million in Series C financing and the appointment of Robert H. Arch, Ph.D., as President and Chief Executive Officer. The financing reflects the continued confidence of the company’s investors in its science, strategy, and team....
Immunophotonics congratulates Professor Wei Chen, co-inventor of IP-001 and a Co-Founder of Immunophotonics, Inc., on receiving an $11.5 million award from the National Institutes of Health (NIH) to establish the Oklahoma Center of ImmunoEngineering (OCIE) at the University of Oklahoma. Led by Professor Wei Chen and Professor Chongle Pan, the new center will bring together...
Immunophotonics has strengthened its global intellectual property portfolio with the issuance of a patent by the China National Intellectual Property Administration (CNIPA). The patent covers the use of the company’s lead asset, IP-001, in combination with checkpoint inhibitors for the treatment of solid tumors. This milestone extends protection of Immunophotonics’ proprietary platform technology into a...
Markus Joerger, M.D., Ph.D. will present new data from a multi-center Phase 1b/2a clinical trial of IP-001 at the American Society of Clinical Oncology (ASCO) Annual Meeting during a poster session on May 30, 2026. The results add to growing momentum in immuno-oncology and further support Immunophotonics’ strategy of converting local tumor treatment into systemic...
Immunophotonics Highlights IP-001 Development at Swiss Biotech Days. Dr. Theresa Visarius, Vice President of Business Development is sharing insights into the ongoing clinical development of IP-001 at Swiss Biotech Days, including a scientific poster session. The work highlights an innovative approach that explores how local tumor ablation may extend beyond direct tumor destruction to help...
Robert, Theresa, and Tomas connecting with partners and peers at ECIO to discuss our work advancing IP-001, aimed at transforming tumor ablation from a local procedure into a systemic cancer therapy. These discussions reflect an ongoing exchange of ideas and insights within interventional therapeutics, supporting the continued advancement of IP-001 through clinical trials. Our focus...
On March 19, the Immunophotonics team was honored to take part in the Worldwide Technology American Cancer Society Shave to Save event at Energizer Park—an inspiring evening dedicated to raising funds for the American Cancer Society Hope Lodge here in St. Louis. Hope Lodge is a truly remarkable nonprofit, providing cancer patients and their caregivers...
Immunophotonics will participate in LSI USA ’26, held March 16–20, 2026, at the Waldorf Astoria Monarch Beach in Dana Point, California. During the conference, Miguel Zubizarreta, CEO, will share company updates and highlight progress in advancing Interventional Immuno‑Oncology®. The presentation is focused on Immunophotonics’ efforts to address cancer recurrence, one of the most significant challenges...
Miguel Zubizarreta, CEO, and Robert Arch, President of Immunophotonics, Inc., are preparing to share key company updates and growth milestones at the LSX Investival Showcase USA, taking place March 10–11, 2026, at the Miami Beach Convention Center. Catch their presentation: March 10 | 12:00 PM at the Biotech Growth Stage Miguel and Robert will highlight...
